SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NeoGenomics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 6, 2023 - (NASDAQ: NEO)

NEW YORK, Feb. 1, 2023

Shareholders who purchased shares of NEO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/neogenomics-loss-submission-form/?id=36064&from=4

CLASS PERIOD: February 27, 2020 to April 26, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

DEADLINE: February 6, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/neogenomics-loss-submission-form/?id=36064&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NEO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 6, 2023. There is no cost or obligation to you to participate in this case.